Celldex Therapeutics Limited

Medarex Inc.

E. R. Squibb Sons, Inc.

Laura A Vitale

Tibor P Keler

Lizhen He

Joel Goldstein

Lawrence J Thomas

Venky Ramakrishna

Karuna Sundarapandiyan

Tom O'Neill

Andrea Crocker

Jenifer Widger

Mohan Srinivasan

Israel Lowy

Henry C Marsh

Diann Blanset

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Agonistic antibodies that bind human CD40 and uses thereof

Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind human CD27 and uses thereof

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

Nucleic acids encoding agonistic antibodies that bind CD40

Agonistic antibodies that bind CD40

Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

[object Object]

The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided.

Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)

Growing community of inventors

Doylestown, PA, United States of America

Laura A Vitale